Genesis Healthcare Inc. (NYSE:GEN) rose 6.5% during trading on Monday . The stock traded as high as $2.14 and last traded at $2.13, with a volume of 148,247 shares. The stock had previously closed at $2.00.

GEN has been the topic of several research reports. Bank of America Corp. cut shares of Genesis Healthcare from a “neutral” rating to an “underperform” rating in a research report on Monday, May 16th. Royal Bank Of Canada cut their price objective on Genesis Healthcare from $5.00 to $3.00 and set an “outperform” rating on the stock in a report on Monday, May 16th. Finally, Stephens downgraded Genesis Healthcare from an “overweight” rating to a “hold” rating in a report on Wednesday, May 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. Genesis Healthcare has an average rating of “Hold” and a consensus target price of $3.50.

The company’s market cap is $191.68 million. The stock has a 50 day moving average of $1.98 and a 200-day moving average of $2.03.

Genesis Healthcare (NYSE:GEN) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.27. The company earned $1.44 billion during the quarter, compared to analyst estimates of $1.40 billion. The firm’s revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.14 EPS.

Genesis Healthcare, Inc, formerly Skilled Healthcare Group, Inc, is a holding company that provides post-acute care. The Company operates through three segments: inpatient services, which includes the operation of skilled nursing facilities and assisted or senior living facilities; rehabilitation therapy services, which includes its integrated and third-party rehabilitation and respiratory therapy services, and all other services, including physician services and other healthcare related services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.